WO2011007327A3 - Suspension for therapeutic use and device for delivering said suspension - Google Patents

Suspension for therapeutic use and device for delivering said suspension Download PDF

Info

Publication number
WO2011007327A3
WO2011007327A3 PCT/IB2010/053229 IB2010053229W WO2011007327A3 WO 2011007327 A3 WO2011007327 A3 WO 2011007327A3 IB 2010053229 W IB2010053229 W IB 2010053229W WO 2011007327 A3 WO2011007327 A3 WO 2011007327A3
Authority
WO
WIPO (PCT)
Prior art keywords
suspension
delivery device
drug delivery
therapeutic use
delivering
Prior art date
Application number
PCT/IB2010/053229
Other languages
French (fr)
Other versions
WO2011007327A2 (en
Inventor
Michel Paul Barbara Van Bruggen
Antonius Wilhelmus Maria De Laat
Original Assignee
Koninklijke Philips Electronics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Electronics N.V. filed Critical Koninklijke Philips Electronics N.V.
Publication of WO2011007327A2 publication Critical patent/WO2011007327A2/en
Publication of WO2011007327A3 publication Critical patent/WO2011007327A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Abstract

The invention provides a suspension for therapeutic use comprising a fluid dispersion medium, particles that are dispersed in the fluid dispersion medium, and a gelling agent, wherein the particles comprise an amorphous and chemically inert matrix in which a drug is dispersed, and wherein the gelling agent is present in an amount in the range of from 0.01-10 % by weight, based on total suspension. Further, a drug delivery device is provided which comprises a reservoir comprising the suspension and a means for releasing a discrete amount of the suspension from the drug delivery device. In addition, the invention relates to a method for preparing the suspension and the use of the suspension and the drug delivery device for the treatment and/or prevention of a disease.
PCT/IB2010/053229 2009-07-16 2010-07-15 Suspension for therapeutic use and device for delivering said suspension WO2011007327A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09165668 2009-07-16
EP09165668.6 2009-07-16

Publications (2)

Publication Number Publication Date
WO2011007327A2 WO2011007327A2 (en) 2011-01-20
WO2011007327A3 true WO2011007327A3 (en) 2011-12-29

Family

ID=42633336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/053229 WO2011007327A2 (en) 2009-07-16 2010-07-15 Suspension for therapeutic use and device for delivering said suspension

Country Status (1)

Country Link
WO (1) WO2011007327A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032402A1 (en) * 2000-10-13 2002-04-25 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
US6669963B1 (en) * 1997-03-18 2003-12-30 Elan Drug Delivery Limited Stable particle in liquid formulations
WO2006083799A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Suspending vehicles comprising a hydrophilic solvent, a hydrophobic solvent, a polymer and the suitable pump-driven dosage form
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562606A1 (en) 2004-04-13 2005-10-27 Cambridge Biostability Limited Liquids containing suspended glass particles
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669963B1 (en) * 1997-03-18 2003-12-30 Elan Drug Delivery Limited Stable particle in liquid formulations
WO2002032402A1 (en) * 2000-10-13 2002-04-25 Cambridge Biostability Ltd. Composition and method for stable injectable liquids
WO2006083799A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Suspending vehicles comprising a hydrophilic solvent, a hydrophobic solvent, a polymer and the suitable pump-driven dosage form
US20060251618A1 (en) * 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon

Also Published As

Publication number Publication date
WO2011007327A2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
WO2006081279A3 (en) Control of drug release by transient modification of local microenvironments
WO2007092179A3 (en) Device with nanocomposite coating for controlled drug release
WO2008060575A3 (en) Drug delivery system and method
WO2013006729A3 (en) Cannabinoid receptor binding agents, compositions and methods
WO2010102196A3 (en) Controlled-release ophthalmic vehicles
WO2009102467A3 (en) Devices, formulations, and methods for delivery of multiple beneficial agents
EP2481409A3 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
WO2008138936A3 (en) Atomizer, and filter
WO2013042125A3 (en) Nano delivery systems for sirna
WO2012019136A3 (en) Injector apparatus and method for drug delivery
EP2346515A4 (en) Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents
WO2008105773A3 (en) System for targeted delivery of therapeutic agents
WO2009086112A3 (en) Apparatus and methods for delivering therapeutic agents
WO2012103038A3 (en) Nanoparticle compositions, formulations thereof, and uses therefor
WO2008094989A3 (en) Punctal plugs and methods of delivering therapeutic agents
WO2012019047A3 (en) Subconjunctival implant for posterior segment drug delivery
WO2008078318A3 (en) Systems and devices for sustained delivery of therapeutic fluid
MX2012007326A (en) Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine.
NZ589542A (en) Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
WO2014106116A3 (en) Therapeutic compositions comprising antibodies
WO2010074992A3 (en) Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2009029958A3 (en) Implantable delivery device
WO2008004890A3 (en) Preservation and controlled delivery/release of spermatozoa
JP2012136529A5 (en)
WO2009067431A3 (en) Controlled drug delivery using a zein layer modified with levulinic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10740373

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10740373

Country of ref document: EP

Kind code of ref document: A2